Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

Göbel, Carl; Heinze, Axel; Karstedt, Sarah; Morscheck, Mascha; Tashiro, Lilian; Cirkel, Anna; Hamid, Qutayba; Halwani, Rabih; Temsah, Mohamad-Hani; Ziemann, Malte; Görg, Siegfried; Münte, Thomas F.; Göbel, Hartmut

doi:10.1093/braincomms/fcab169

Cited by 63 publications

(93 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 38% and 32% of the cases, headache occurred in a frontal or temporal distribution, respectively 6 . Headache was characterized as dull in 40%, and intensity was very severe in 8.2%, severe in 32.1%, and moderate in 46.2% 6 . According to one of the registration studies for the AZV, headache was the most frequent neurological complication of SARS‐CoV‐2 vaccinations without providing an exact figure of the headache frequency 7 .…”

Section: Resultsmentioning

confidence: 99%

“…Headache is by far the most frequent neurological side effect of SARS‐CoV‐2 vaccinations and occurs with any of the approved vaccines. In the majority of cases, headache starts within a few hours after the vaccination and resolves spontaneously within 48 h 6 . However, a subacute type of headache has been delineated which occurs on the average 8 days after the shot and is frequently associated with VST 16 .…”

Section: Discussionmentioning

confidence: 99%

“…In a recent multinational, multicenter observational cohort study by means of a standardized questionnaire, among inhabitants of residential care homes of the elderly and patients from hospitals, 2349 patients reported headache after vaccination with the Pfizer vaccine. 6 Headache started on the average 18 h after the shot and lasted on the average for 14 h. 6 In two thirds of these cases, headache manifested with a single episode. In 38% and 32% of the cases, headache occurred in a frontal or temporal distribution, respectively.…”

Section: Re Sultsmentioning

confidence: 99%

See 2 more Smart Citations

Neurological side effects of SARS‐CoV‐2 vaccinations

Finsterer

2021

Acta Neuro Scandinavica

139

117

View full text Add to dashboard Cite

Though SARS-CoV-2 vaccinations are usually sold as well tolerated, they can cause mild-to-severe side effects in some patients. 1 Since the benefit for the global population outweighs these adverse reactions, and since political and pecuniary interests create the image of a "safe and indispensable" tool against the currently dominant global burden, there is only moderate reporting and discussion about them. 2There is also an anti-vaccine movement in the world nowadays that also contributes to the biased assessment of these adverse effects.Usually, single case reports, case series, or registration studies report these side effects but systematic, transnational, multicenter, postmarketing investigations on this matter are infrequently done. This shortage of published information about type, frequency, severity, and therapeutic management of vaccination-related side effects is in contradiction to the daily experience of healthcare workers and affected probands, and may contribute to the individual or organized resistance and reservations against the vaccination from parts of the populations, the only moderate effect of vaccination campaigns, and the tendency to introduce compulsory vaccination. 3 Neurological side effects to SARS-CoV-2 vaccinations are usually mild, of short duration, self-limiting, and ambulatorily manageable.However, in some cases, these side effects are severe and require hospitalization or even admission to an intensive care unit (ICU). 4 Only, rarely these side effects can be fatal. 5 Since the virus and the adverse reactions to vaccinations show a tropism for neuronal structures and tissues this narrative review about the neurological side effects was conducted to collect and discuss published data in order to discover type, frequency, treatment, and outcome of these side effects and to eventually discover if certain patients are prone to

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

See 1 more Smart Citation

Neurological side effects of SARS‐CoV‐2 vaccinations

Finsterer

2021

Acta Neuro Scandinavica

139

117

View full text Add to dashboard Cite

show abstract

“…Contrarily, no precise information regarding the clinical phenotype is contained in these studies. Whether the headache phenotype described here occurs in the same way or in a different form with other vaccines against COVID-19 remains still open and is subject to further subgroup analyses in this study series [39].…”

Section: --------------------------------------------------------------------------------------------------------------------------------mentioning

confidence: 89%

Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction The most frequently reported neurological adverse event of ChAdOx1 nCoV-19 (AZD1222) vaccine is headache in 57.5%. Several cases of cerebral venous thrombosis (CVT) have developed after vaccination. Headache is the leading symptom of CVT. For the differential diagnosis of headaches attributed to this vaccine and headaches attributed to CVT, it is of central clinical importance whether and, if so, how the phenotypes and course of these headaches can be differentiated. The study aims to examine in detail the phenotype of headache attributed to this vaccine. Methods Data on the clinical features and corresponding variables were recorded using a standardized online questionnaire in this multicenter observational cohort study. The primary outcomes of this study are the clinical features of headaches after vaccination. Findings A total of 2464 participants reported headaches after vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine. On average, headaches occurred 14.5 ± 21.6 h after vaccination and lasted 16.3 ± 30.4 h. A bilateral location was described by 75.8% of participants. This is most often found on the forehead (40.0%) and temples (31.4%); 50.4% reported a pressing and 37.7% a dull pain character. Headache intensity was most often severe (38.7%), moderate (35.2%), or very severe (15.5%). Accompanying symptoms were most commonly fatigue (44.8%), chills (36.1%), exhaustion (34.9%), and fever (30.4%). Conclusion Headaches attributed to COVID-19 vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine demonstrate an extensive and characteristic complex of symptoms. The findings have several important clinical implications for the differentiation of post-vaccinal headache and other primary as well as secondary headaches.

show abstract

“…According to literature, headache is one of the most frequent side effects due to coronavirus disease-19 (COVID-19) vaccines [ 2 ]. In the population vaccinated with Comirnaty (Pfizer/BioNtech) vaccine, both migraine and tension-type headaches have been described.…”

Section: Introductionmentioning

confidence: 99%